News | Webinars | Publications | Conferences | Upcoming Events |
Alx4 relays sequential FGF signaling to induce lacrimal gland morphogenesis
Garg A, Bansal M, Gotoh N, Feng G-S, Zhong J, Wang F, Kariminejad A, Brooks S, Zhang X.
PLoS Genet. 2017 Oct 13. 13(10):e1007047. doi: 10.1371/journal.pgen.1007047. eCollection 2017 Oct.
Synergistic antileukemic therapies in NOTCH1-induced T-ALL.
Sanchez-Martin M, Ambesi-Impiombato A, Qin Y, Herranz D, Bansal M, Girardi T, Paietta E, Tallman M S, Rowe J M, De Keersmaecker K, Califano A, Ferrando A A.
Proceedings of the National Academy of Sciences. 2017 Feb 21. 114(8):2006-2011. doi: 10.1073/pnas.1611831114. Epub 2017 Feb 7.
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response
Zhang X, Maity T, Kashyap M K, Bansal M, Venugopalan A, Singh S, Awasthi S, Marimuthu A, Jacob H K C, Belkina N, Pitts S, Cultraro C M, Gao S, Kirkali G, Biswas R, Chaerkady R, Califano A, Pandey A, Guha U.
Mol Cell Proteomics . 2017 May. 16(5):891-910. doi: 10.1074/mcp.M117.067439. Epub 2017 Mar 22.
High-throughput validation of ceRNA regulatory networks
Chiu H-S, Martínez M R, Bansal M, Subramanian S, Golub T R, Yang X, Sumazin P, Califano A .
BMC Genomics. 2017 May 30. 18(1):418. doi: 10.1186/s12864-017-3790-7.
Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity
Udyavar A R, Wooten D J, Hoeksema M, Bansal M, Califano A, Estrada L, Schnell S, Irish J M, Massion P P, Quaranta V .
Cancer Res. 2017 Mar 1. 77(5):1063-1074. doi: 10.1158/0008-5472.CAN-16-1467. Epub 2016 Dec 8.
Bone morphogenetic protein and Notch signalling crosstalk in poor-prognosis, mesenchymal-subtype colorectal cancer
Irshad S, Bansal M, Guarnieri P, Davis H, Zen A.L, Baran B, Pinna C.M, Rahman H, Biswas S, Bardella C, Jeffery R, Wang L.M, East J.E, Lewis A, Tomlinson I, Leedham S.J .
The Journal of Pathology 2017 242 (2). 178-192. doi: 10.1002/path.4891. Epub 2017 May 3.
Phosphodiesterase 10 inhibition improves cortical – basal ganglia function in Huntington’s Disease models.
Beaumont V, Zhong Z, Xu W.J, Lin H, Bradaia A, Steidl E, Gleyzes M, Wadel K, Buisson B, Neto F.P, Chakroborty S, Ward K, Harms J.F, Beltran J, Kwan M, Ghavami A, Häggkvist J, Tóth M, Halldin C, Andrea Varrone, Schaab C, D. J. Nikolaj, Elschenbroich S, Park L, Rosinski J, Mrzljak L, Lavery D, West A, Schmidt C, Zaleska M, Munoz-Sanjuan I.
Neuron. 2016 Dec 21. 92(6):1220-1237. doi: 10.1016/j.neuron.2016.10.064. Epub 2016 Dec 1.
Large-scale phenome analysis defines a behavioral signature for Huntington’s disease genotype in mice.
Alexandrov V, Brunner D, Menalled LB, Kudwa A, Watson-Johnson J, Mazzella M, Russel I, Ruiz MC, Torello J, Sabath E, Sanchez A, Gomez M, Filipov I, Cox K, Kwan M, Ghavami A, Ramboz S, Lager B2, Wheeler VC, Aaronson J, Rosinski J, Gusella JF, MacDonald ME, Howland D, Kwak S.
Nat Biotechnol. 2016 Aug. 34(8):838-44. doi: 10.1038/nbt.3587. Epub 2016 Jul 4.
In Vivo Phenotypic Drug Discovery: Applying a Behavioral Assay to the Discovery and Optimization of Novel Antipsychotic Agents. Med. Chem. Commun,.
Shao L, Campbell U, Fang K, Powell AN, Campbell JE, Jones PG, Hanania T, Alexandrov V, Morganstern I, Sabath E, Zhong MH, Large HT, Spear KL
2016. 1093-1101
Comprehensive Analysis of the 16p11.2 Deletion and Null Cntnap2 Mouse Models of Autism Spectrum Disorder.
Brunner D., Kabitzke P., He D., Cox K., Thiede L., Hanania T., He D., Sabath E., Alexandrov V., Saxe M., Peles E., Mills A., Spooren W., Ghosh A., Feliciano P., Benedetti M., Clayton AL., Biemans B.
PLoS One. 2015 Aug 14. 10(8):e0134572. doi: 10.1371/journal.pone.0134572. eCollection 2015.
High-throughtput analysis of behavior for drug discovery
Alexandrov V, Brunner D, Hanania T, Leahy E
Eur J Pharmacol. 2015 Mar 5. 750:82-9. doi: 10.1016/j.ejphar.2014.11.047. Epub 2015 Jan 12.
Effect of a novel, orally active matrix metalloproteinease-2 and-9 inhibitor in spinal and trigeminal rat models of neuropathic pain
Michael A Henry, Dara D Fairchild, Mayur J Patil, Taleen Hanania, Heather S Hain, Scott F Davis, Sam A Malekiani, Andrew Hu, Roy Sucholeiki, Darrell Nix, Irving Sucholeiki
J Oral Facial Pain Headache. 2015 Summer. 29(3):286-96. doi: 10.11607/ofph.1350.
Animal Models of Huntington’s Disease for Translation to the Clinic: Best Practices. Movement Disorders
Menalled L & Brunner D.
Mov Disord. 2014 Sep 15. 29(11):1375-90. doi: 10.1002/mds.26006.
Genetic Deletion of Transglutaminase 2 Does Not Rescue the Phenotypic Deficits Observed in R6/2 and zQ175 Mouse Models of Huntington’s Disease
Menalled LB, Kudwa A, Oakeshott S, Farrar A, Paterson N, Filippov I, Miller S, Kwan M, Olsen M, Beltran J, Torello J, Fitzpatrick J, Mushlin R, Cox K, McConnell K, Mazzella M, He D, Osborne GF, Al-Nackkash R, Bates GP, Tuunanen P, Lehtimaki K, Brunner D, Ghavami A, Ramboz S, Park L, Macdonald D, Munoz-Sanjuan I, Howland D
PLoS One. 2014 Jun 23. 9(6):e99520. doi: 10.1371/journal.pone.0099520. eCollection 2014.
Phenotypic characterization of recessive gene knockout rat models of Parkinson’s disease
Kuldip D. Dave, Shehan De Silv, Niketa P. Sheth, Sylvie Ramboz, Melissa J. Beck, Changyu Quang, Robert C. Switzer III, Syed O. Ahmad, Susan M. Sunkin, Dan Walker, Xiaoxia Cui, Daniel A. Fisher, Aaron M. McCoy, Kevin Gamber, Xiaodong Ding, Matthew S. Goldberg, Stanley A. Benkovic, Meredith Haupt, Marco A.S. Baptista, Brian K. Fiske, Todd B. Sherer, Mark A. Frasier
Neurobiol Dis. 2014 Oct. 70:190-203. doi: 10.1016/j.nbd.2014.06.009. Epub 2014 Jun 24.
High-Throughput Automated Phenotyping of Two Genetic Mouse Models of Huntington’s Disease.
Balci F, Oakeshott S, Shamy J.S., El-Khodor B.F., Filippov I, Mushlin R, Port R, Connor D, Paintdakhi A, Menalled L, Ramboz S, Howland D, Kwa S, Brunner D
PLoS Curr. 2013 Jul 11. 5:ecurrents.hd.124aa0d16753f88215776fba102ceb29. doi: 10.1371/currents.hd.124aa0d16753f88215776fba102ceb29.
Regional vulnerability in Huntington’s disease: fMRI-guided molecular analysis in patients and a mouse model of disease
Moreno H, Lewandowski N, Bordelon Y, Brickman A, Angulo S, Khan U, Muraskin J, Griffith E, Wasserman P, Menalled L, Vonsattel J.P, Marder K, Small S.A
Neurobiol Dis. 2013 Apr. 52:84-93. doi: 10.1016/j.nbd.2012.11.014. Epub 2012 Dec 4.
Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175
Menalled L, Kudwa A, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, Ruiz M, Mushlin R, Alosio B, McConnell K, Connor D, Murphy C, Oakeshott S, Kwan M, Beltran J, Ghavami A, Brunner D, C. Park L, Ramboz S and Howland D
PLoS One. 2012. 7(12):e49838. doi: 10.1371/journal.pone.0049838. Epub 2012 Dec 20.
Insights into the Structural Determinants Required for High Affinity Binding of Chiral Cyclopropane-Containing Ligands to α4β2-Nicotinic Acetylcholine Receptors; An Integrated Approach to Behaviorally Active Nicotinic Ligands.
Zhang HK, Eaton JB, Yu LF, Nys M, Mazzolari A, van Elk R, Smit AB, Alexandrov V, Hanania T, Sabath E, Fedolak A, Brunner D, Lukas RJ, Vistoli G, Ulens C, Kozikowski AP.
J Med Chem. 2012 Sep 27. 55(18):8028-37. doi: 10.1021/jm3008739. Epub 2012 Sep 7.
Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity .
S. Stefanie, H Bettina, Nilges M, Schroeder S, Hoelich A, Keletzl H, Spooren W, Ostrowitzki S, Hanania T, Sendtner M, Metzger F.
Amyotroph Lateral Scler. 2012 Sep. 13(5):418-29. doi: 10.3109/17482968.2012.679944. Epub 2012 Aug 7.
Prediction of Death in the SMNΔ Mouse Model of Spinal Muscular Atrophy: Insight into Disease Stage and Progression. Journal of Neuroscience Methods.
El-Khodor BF, Cirillo K, Beltran JA, Mushlin R, Winberg ML, Charney R, Chomicova O, Marino T, Ramboz S.
J Neurosci Methods. 2012 Aug 15. 209(2):259-68. doi: 10.1016/j.jneumeth.2012.06.020. Epub 2012 Jun 29.
Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of Ä7 SMA KO Mouse Model of Spinal Muscular Atrophy.
Chen PC, Gaisina IN, El-Khodor BF, Ramboz S, Makhortova NR, Rubin LL, Kozikowski AP.
ACS Chem Neurosci. 2012 Jan 18. 3(1):5-11. doi: 10.1021/cn200085z.
Effect of the rd1 mutation on motor performance in R6/2 and wild type mice. PLoS Currents Huntington Disease.
Menalled, L., El-Khodor, B. F., Hornberger, M., Park, L., Howland, D., and Brunner, D.
PLoS Curr. 2012 Feb 13. 4:RRN1303. doi: 10.1371/currents.RRN1303.
Identification of Novel alpha4 beta2-Nicotinic Acetylcholine Receptor (nAChR) Agonists Based on an Isoxazole Ether Scaffold that Demonstrate Antidepressant-like Activity. Journal of medicinal chemistry.
Yu, L. F., Tuckmantel, W., Eaton, J. B., Caldarone, B., Fedolak, A., Hanania, T., Brunner, D., Lukas, R. J., and Kozikowski, A. P.
J Med Chem 2012 Jan 26. 55(2):812-23. doi: 10.1021/jm201301h. Epub 2012 Jan 4.
Behavior-Based Screening as an Approach to Polypharmacological Ligands, in Polypharmacology in Drug Discovery.
Brunner, D., Alexandrov, V., Caldarone, B., Hanania, T., Lowe, D., Schneider, J., and Chandrasekhar, J.
John Wiley & Sons, Inc. pp 301-309.
R6/2 Huntington’s disease Mice Develop Early and Progressive Abnormal Brain Metabolism and Seizures.
Efrain Cepeda-Prado, Susanna Popp, Usman Khan, Dimitre Stefanov, Jorge Rodrguez, Liliana Menalled, Diana Dow-Edwards, Scott Small, and Herman Moreno
J Neurosci. 2012 May 9. 32(19):6456-67. doi: 10.1523/JNEUROSCI.0388-12.2012.
Caspase-6 activity in a BAC HD mouse modulates steady state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.
Juliette Gafni, Theodora Papanikolaou, Francesco DeGiacomo, Jennifer Holcomb, Sylvia Chen, Menalled L.; Kudwa A.; Jon Fitzpatrick, Miller S.; Ramboz S.; Pasi Tuunanen, Kimmo Lehtimaki, Xiangdong William Yang, Seung Kwak, Larry Park, David Howland, Hyunsun Park, and Lisa Ellerby
J Neurosci. 2012 May 30. 32(22):7454-65. doi: 10.1523/JNEUROSCI.6379-11.2012.
Behavior-based screening as an approach to polypharmacological ligands.
Brunner, D.; Alexandrov, V.; Chandrasekhar, J.; Hanania, T.; Caldarone, B.; Lowe, D.; Schneider J.
In Polypharmacology in Drug Discovery, Peters, J.-U., Ed. John Wiley & Sons, Inc. 2011. DOI 1D.10.1002/9781118098141.ch4.
Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms,
Roberds, S. L., Filippov, I., Alexandrov, V., Hanania, T., and Brunner, D.
Front Neurosci. 2011 Sep 9. 5:103. doi: 10.3389/fnins.2011.00103. eCollection 2011.
HD mouse models reveal clear deficits in learning to perform a simple instrumental response. PLoS Currents: Huntington Disease.
Oakeshott, S., Port, R. G., Cummins-Sutphen, J., Watson-Johnson, J., Ramboz, S., Park, L., Howland, D., and Brunner, D.
PLoS Curr. 2011 Nov 30. 3:RRN1282. doi: 10.1371/currents.RRN1282.
Discovery of Isoxazole Analogs of Sazetidine-A as Selective alpha4 beta2-Nicotinic Acetylcholine Receptor (nAChR) Partial Agonists for the Treatment of Depression,
Liu, J., Yu, L. F., Eaton, J. B., Caldarone, B., Cavino, K., Ruiz, C., Terry, M., Fedolak, A., Wang, D., Ghavami, A., Lowe, D. A., Brunner, D., Lukas, R. J., Kozikowski, A. P.
J Med Chem. 2011 Oct 27. 54(20):7280-8. doi: 10.1021/jm200855b. Epub 2011 Sep 30.
Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration,
Brunner, D., Balci, F., and Ludvig, E. A.
Behav Processes. 2012 Feb. 89(2):187-95. doi: 10.1016/j.beproc.2011.10.011. Epub 2011 Dec 7.
Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington’s Disease.
Oakeshott S, Balci F, Filippov I, Murphy C, Port R, Connor D, Paintdakhi A, Lesauter J, Menalled L, Ramboz S, Kwak S, Howland D, Silver R, Brunner D.
PLoS Curr. 2011 Apr 5. 3:RRN1225. doi: 10.1371/currents.RRN1225.
Effect of the rd1 mutation on motor performance in R6/2 and wild type mice [Internet]. Version 28.
Liliana M.; El-Khodor B F.; Hornberger M.; Park, Larry; Howland, David; Brunner D.
PLoS Curr. 2012 Feb 13. 4:RRN1303. doi: 10.1371/currents.RRN1303.
Impulsive action and impulsive choice are mediated by distinct neuropharmacological substrates in rat
Paterson N.E., Wetzler C., Hackett A., Hanania T.
Int J Neuropsychopharmacol. 2012 Nov. 15(10):1473-87. doi: 10.1017/S1461145711001635. Epub 2011 Nov 18.
Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms.
Steven L Roberts, Filippov I.; Alexandrov V.; Hanania T.; Brunner D.
Front Neurosci. 2011 Sep 9. 5:103. doi: 10.3389/fnins.2011.00103. eCollection 2011.
Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone.
Paterson, N. E.; Ricciardi, J.; Wetzler, C.; Hanania, T.
Neurosci Res. 2011 Jan. 69(1):41-50. doi: 10.1016/j.neures.2010.10.001. Epub 2010 Oct 8.
Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats.
Kehr, J.; Ichinose, F.; Yoshitake, S.; Goiny, M.; Sievertsson, T.; Nyberg, F.; Yoshitake, T.
Br J Pharmacol. 2011 Dec. 164(8):1949-58. doi: 10.1111/j.1476-5381.2011.01499.x.
Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington’s Disease.
Oakeshott, S.; Balci, F.; Filippov, I.; Murphy, C.; Port, R.; Connor, D.; Paintdakhi, A.; Lesauter, J.; Menalled, L.; Ramboz, S.; Kwak, S.; Howland, D.; Silver, R.; Brunner, D.
PLoS Curr. 2011 Apr 5. 3:RRN1225. doi: 10.1371/currents.RRN1225.
Histopathological and neurological features of Atg4b knockout mice.
Read, R.; Savelieva, K.; Baker, K.; Hansen, G.; Vogel, P.
Vet Pathol. 2011 Mar. 48(2):486-94. doi: 10.1177/0300985810375810. Epub 2010 Jul 15.
Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380.
Caldarone, B. J.; Wang, D.; Paterson, N. E.; Manzano, M.; Fedolak, A.; Cavino, K.; Kwan, M.; Hanania, T.; Chellappan, S. K.; Kozikowski, A. P.; Olivier, B.; Picciotto, M. R.; Ghavami, A.
Psychopharmacology (Berl). 2011 Sep. 217(2):199-210. doi: 10.1007/s00213-011-2271-y. Epub 2011 Apr 13.
The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.
Paterson, N. E.; Balci, F.; Campbell, U.; Olivier, B. E.; Hanania, T.
J Psychopharmacol. 2011 Oct. 25(10):1357-64. doi: 10.1177/0269881110364272. Epub 2010 Mar 19.
Comparison of the predictive validity of the mirror chamber and elevated plus maze tests in mice.
Paterson, N. E.; Iwunze, M.; Davis, S. F.; Malekiani, S. A.; Hanania, T.
J Neurosci Methods. 2010 Apr 30. 188(1):62-70. doi: 10.1016/j.jneumeth.2010.02.005. Epub 2010 Feb 10.
Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments.
Baker, K.; Wray, S.; Ritter, R.; Mason, S.; Lanthorn, T.; Savelieva, K.
Genes Brain Behav. 2010 Aug. 9(6):562-74. doi: 10.1111/j.1601-183X.2010.00585.x. Epub 2010 Apr 6.
The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
Caldarone, B. J.; Paterson, N. E.; Zhou, J.; Brunner, D.; Kozikowski, A. P.; Westphal, K. G.; Korte-Bouws, G. A.; Prins, J.; Korte, S. M.; Olivier, B.; Ghavami, A
J Pharmacol Exp Ther. 2010 Dec. 335(3):762-70. doi: 10.1124/jpet.110.174011. Epub 2010 Sep 23.
Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.
Paterson, N. E.; Fedolak, A.; Olivier, B.; Hanania, T.; Ghavami, A.; Caldarone, B.
Pharmacol Biochem Behav. 2010 Jun. 95(4):449-56. doi: 10.1016/j.pbb.2010.03.006. Epub 2010 Mar 25.
The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.
Paterson, N. E.; Min, W.; Hackett, A.; Lowe, D.; Hanania, T.; Caldarone, B.; Ghavami, A.
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1. 34(8):1455-64. doi: 10.1016/j.pnpbp.2010.07.037. Epub 2010 Aug 11.
Comprehensive behavioral testing in the R6/2 mouse model of Huntington’s disease shows no benefit from CoQ10 or minocycline.
Menalled, L. B.; Patry, M.; Ragland, N.; Lowden, P. A.; Goodman, J.; Minnich, J.; Zahasky, B.; Park, L.; Leeds, J.; Howland, D.; Signer, E.; Tobin, A. J.; Brunner, D.
PLoS One. 2010 Mar 22. 5(3):e9793. doi: 10.1371/journal.pone.0009793.
Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments. Genes, Brain and Behavior
Baker, K.; Wray, S.; Ritter, R.; Mason, S.; Lanthorn, T.; Savelieva, K.
Genes Brain Behav. 2010 Aug. 9(6):562-74. doi: 10.1111/j.1601-183X.2010.00585.x. Epub 2010 Apr 6.
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson’s disease: studies with the P2X(7) receptor antagonist A-438079.
Marcellino, D.; Suárez-Boomgaard, D.; Sánchez-Reina, M.D.; Aguirre, J.A.; Yoshitake, T.; Yoshitake, S.; Hagman, B.; Kehr, J.; Agnati, L.F.; Fuxe, K.; Rivera, A.
J Neural Transm (Vienna). 2010 Jun. 117(6):681-7. doi: 10.1007/s00702-010-0400-0. Epub 2010 Apr 13.
MitoPark mice mirror the slow progression of key Parkinson disease symptoms and the L-DOPA response. Genes, Brain and Behavior
Galter, D.; Pernold, K.; Yoshitake, T.; Lindqvist, E.; Kehr, J.; Olson, L.
Genes Brain Behav. 2010 Mar 1. 9(2):173-81. doi: 10.1111/j.1601-183X.2009.00542.x. Epub 2009 Oct 7.
Anxiolytic effects of lamotrigine and JZP-4 in the elevated plus maze and in the four plate conflict test.
Foreman, M. M.; Hanania, T.; Eller, M.
Eur J Pharmacol. 2009 Jan 14. 602(2-3):316-20. doi: 10.1016/j.ejphar.2008.11.013. Epub 2008 Nov 17.
Reward-seeking and discrimination deficits displayed by hypodopaminergic mice are prevented in mice lacking dopamine D4 receptors.
Nemirovsky, S. I.; Avale, M. E.; Brunner, D.; Rubinstein, M.
Synapse. 2009 Nov. 63(11):991-7. doi: 10.1002/syn.20680.
Acquisition of peak responding
Balci, F.; Gallistel, C. R.; Allen, B. D.; Frank, K. M.; Gibson, J. M.; Brunner, D.
Behav Processes. 2009 Jan. 80(1):67-75. doi: 10.1016/j.beproc.2008.09.010. Epub 2008 Oct 4.
Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains.
Mason, S. S.; Baker, K. B.; Davis, K. W.; Pogorelov, V. M.; Malbari, M. M.; Ritter, R.; Wray, S. P.; Gerhardt, B.; Lanthorn, T.H.; Savelieva, K.V.
Eur J Pharmacol. 2009 Jan 14. 602(2-3):306-15. doi: 10.1016/j.ejphar.2008.11.010. Epub 2008 Nov 12.
Behavioural and pharmacological mechanisms of bupropion’s anti-smoking effects: recent preclinical and clinical insights.
Paterson, N. E.
Eur J Pharmacol. 2009 Jan 28. 603(1-3):1-11. doi: 10.1016/j.ejphar.2008.12.009. Epub 2008 Dec 16.
The neuropharmacological substrates of nicotine reward: reinforcing versus reinforcement-enhancing effects of nicotine.
Paterson, N. E.
Behav Pharmacol. 2009 May. 20(3):211-25. doi: 10.1097/FBP.0b013e32832c7083.
Pharmacological characterization of harmaline-induced tremor activity in mice.
Paterson, N. E.; Malekiani, S. A.; Foreman, M. M.; Olivier, B.; Hanania, T.
Eur J Pharmacol. 2009 Aug 15. 616(1-3):73-80. doi: 10.1016/j.ejphar.2009.05.031. Epub 2009 Jun 2.
Systematic behavioral evaluation of Huntington’s disease transgenic and knock-in mouse models.
Menalled, L.; El-Khodor, B. F.; Patry, M.; Suarez-Farinas, M.; Orenstein, S. J.; Zahasky, B.; Leahy, C.; Wheeler, V.; Yang, X. W.; MacDonald, M.; Morton, A. J.; Bates, G.; Leeds, J.; Park, L.; Howland, D.; Signer, E.; Tobin, A.; Brunner, D
Neurobiol Dis. 2009 Sep. 35(3):319-36. doi: 10.1016/j.nbd.2009.05.007. Epub 2009 May 21.
GABAa receptor α1 subunit (Gabra1) knockout mice: review and new results. In Mutant and Transgenic Tools in Modeling Brain Disorders
Ye, G-L.; Baker, K.B.; Mason, S.M.; Zhang, W.; Kirkpatrick, L.; Lanthorn, T.H.; Savelieva, K.V.
Kalueff, AV; Bergner, CL, Ed. Humana Press: 2009, 65-90.
Loss of the putative catalytic domain of HDAC4 leads to reduced thermal nociception and seizures while allowing normal bone development.
Rajan, I.; Savelieva, K.V.; Ye, G-L.; Wang, C-Y.; Malbari, M. M.; Friddle, C.; Lanthorn, T.H.; Zhang, W.
PLoS One. 2009 Aug 12. 4(8):e6612. doi: 10.1371/journal.pone.0006612.
Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm.
Vinkers, C. H.; van Bogaert, M. J.; Klanker, M.; Korte, S. M.; Oosting, R.; Hanania, T.; Hopkins, S. C.; Olivier, B.; Groenink, L.
Eur J Pharmacol. 2008 May 13. 585(2-3):407-25. doi: 10.1016/j.ejphar.2008.02.097. Epub 2008 Mar 18.
Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic.
Day, M.; Balci, F.; Wan, H. I.; Fox, G. B.; Rutkowski, J. L.; Feuerstein, G.
Curr Opin Investig Drugs. 2008 Jul. 9(7):696-706.
Learning and memory impairment in Eph receptor A6 knockout mice.
Savelieva, K. V.; Rajan, I.; Baker, K. B.; Vogel, P.; Jarman, W.; Allen, M.; Lanthorn, T. H.
Neurosci Lett. 2008 Jun 20. 438(2):205-9. doi: 10.1016/j.neulet.2008.04.013. Epub 2008 Apr 10.
Interval timing in genetically modified mice: a simple paradigm.
Balci, F.; Papachristos, E. B.; Gallistel, C. R.; Brunner, D.; Gibson, J.; Shumyatsky, G. P.
Genes Brain Behav. 2008 Apr. 7(3):373-84. doi: 10.1111/j.1601-183X.2007.00348.x. Epub 2007 Aug 13.
Pharmacological manipulations of interval timing using the peak procedure in male C3H mice.
Balci, F.; Ludvig, E. A.; Gibson, J. M.; Allen, B. D.; Frank, K. M.; Kapustinski, B. J.; Fedolak, T. E.; Brunner, D
Psychopharmacology (Berl). 2008 Nov. 201(1):67-80. doi: 10.1007/s00213-008-1248-y. Epub 2008 Jul 23.
The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects.
Breuer, M. E.; Chan, J. S.; Oosting, R. S.; Groenink, L.; Korte, S. M.; Campbell, U.; Schreiber, R.; Hanania, T.; Snoeren, E. M.; Waldinger, M.; Olivier, B.
Eur Neuropsychopharmacol. 2008 Dec. 18(12):908-16. doi: 10.1016/j.euroneuro.2008.07.011. Epub 2008 Sep 11.
Learning and memory impairment in Eph receptor A6 knockout mice.
Savelieva, K. V.; Rajan, I.; Baker, K. B.; Vogel, P.; Jarman, W.; Allen, M.; Lanthorn, T. H.
Neurosci Lett. 2008 Jun 20. 438(2):205-9. doi: 10.1016/j.neulet.2008.04.013. Epub 2008 Apr 10.
Interval timing in genetically modified mice: a simple paradigm.
Balci, F.; Papachristos, E. B.; Gallistel, C. R.; Brunner, D.; Gibson, J.; Shumyatsky, G. P.
Genes Brain Behav. 2008 Apr. 7(3):373-84. doi: 10.1111/j.1601-183X.2007.00348.x. Epub 2007 Aug 13.
In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity.
Foreman, M. M.; Hanania, T.; Stratton, S. C.; Wilcox, K. S.; White, H. S.; Stables, J. P.; Eller, M.
Pharmacol Biochem Behav. 2008 Jun. 89(4):523-34. doi: 10.1016/j.pbb.2008.02.007. Epub 2008 Feb 11.
Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods.
Houghten, R. A.; Pinilla, C.; Giulianotti, M. A.; Appel, J. R.; Dooley, C. T.; Nefzi, A.; Ostresh, J. M.; Yu, Y.; Maggiora, G. M.; Medina-Franco, J. L.; Brunner, D.; Schneider, J.
J Comb Chem. 2008 Jan-Feb. 10(1):3-19. doi: 10.1021/cc7001205. Epub 2007 Dec 8.
Timing Deficits in Neuropathology In Cognitive Aging: Integrating Models.
Balci, F.; Moore, H.; Brunner, D.
Humana Press: Wagner, L.A., 2008.
Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy.
El-Khodor, B. F.; Edgar, N.; Chen, A.; Winberg, M. L.; Joyce, C.; Brunner, D.; Suarez-Farinas, M.; Heyes, M. P.
Exp Neurol 2008 Jul. 212(1):29-43. doi: 10.1016/j.expneurol.2008.02.025. Epub 2008 Mar 18.
Huntington Disease. In Animal and Translational Models of Behavioral Disorders
Menalled, L.; Gomeniouk, A.; Brunner, D.; Leavitt, B. R.
Borsini, R. M. a. F., Ed. Elsevier: 2008.
Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy.
El-Khodor, B. F.; Edgar, N.; Chen, A.; Winberg, M. L.; Joyce, C.; Brunner, D.; Suarez-Farinas, M.; Heyes, M. P.
Exp Neurol. 2008 Jul. 212(1):29-43. doi: 10.1016/j.expneurol.2008.02.025. Epub 2008 Mar 18.
Standardized Behavioral Test Battery to Identify and Validate Targets for Neuropsychiatric Diseases and Pain.
Pogorelov, V.M.; Baker, K.B.; Malbari, M.M.; Lanthorn, T.H.; Savelieva, K.V.
In Experimental models in neurobehavioral research, Kalueff AV, LaPorte JL, Ed. Nova Science Publishers: 2008, 17-46.
Genetic disruption of both tryptophan hydroxylase genes strongly reduces serotonin in the brain and affects behavior in models sensitive to antidepressants
Savelieva, K.V.; Zhao, S.; Pogorelov, V.M.; Rajan, I.; Yang, Q.; Cullinan, E.; Lanthorn, T.H.
PLoS One. 2008. 3(10):e3301. doi: 10.1371/journal.pone.0003301. Epub 2008 Oct 15.
Netrin-G2 and netrin-G2 ligand are both required for normal auditory responsiveness.
Zhang, W.; Rajan, I.; Savelieva, K.V.; Wang, C-Y.; Vogel, P.; Kelly, M.; Xu, N.; Hasson, B.; Jarman, W.; Lanthorn, T.H.
Genes Brain Behav. 2008 Jun. 7(4):385-92. doi: 10.1111/j.1601-183X.2007.00361.x. Epub 2007 Oct 31.
Use of a platform in an automated open-field to enhance assessment of anxiety-like behaviors in mice.
Pogorelov, V.M.; Lanthorn, T.H.; Savelieva KV.
J Neurosci Methods. 2007 May 15. 162(1-2):222-8. doi: 10.1016/j.jneumeth.2007.01.015. Epub 2007 Jan 26.
Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation.
Kehr, J.; Hu, X. J.; Goiny, M.; Scheller, D. K.
J Neural Transm (Vienna). 2007. 114(8):1027-31. doi: 10.1007/s00702-007-0719-3. Epub 2007 Apr 16.
Measurement of brain microglial proliferation rates in vivo in response to neuroinflammatory stimuli: application to drug discovery.
Shankaran, M.; Marino, M. E.; Busch, R.; Keim, C.; King, C.; Lee, J.; Killion, S.; Awada, M.; Hellerstein, M. K.
J Neurosci Res. 2007 Aug 15. 85(11):2374-84. doi: 10.1002/jnr.21389.
Measurement of cell proliferation by heavy water labeling.
Busch, R.; Neese, R. A.; Awada, M.; Hayes, G. M.; Hellerstein, M. K.
Nat Protoc. 2007. 2(12):3045-57. doi: 10.1038/nprot.2007.420.
Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders.
Roy, K.; Murtie, J. C.; El-Khodor, B. F.; Edgar, N.; Sardi, S. P.; Hooks, B. M.; Benoit-Marand, M.; Chen, C.; Moore, H.; O'Donnell, P.; Brunner, D.; Corfas, G.
Proc Natl Acad Sci U S A . 2007 May 8;104(19):8131-6. doi: 10.1073/pnas.0702157104. Epub 2007 May 1.
Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
Kozikowski, A. P.; Gaisina, I. N.; Yuan, H.; Petukhov, P. A.; Blond, S. Y.; Fedolak, A.; Caldarone, B.; McGonigle, P.
J Am Chem Soc. 2007 Jul 4. 129(26):8328-32. doi: 10.1021/ja068969w. Epub 2007 Jun 7.
Exploring neurocircuitries of the basal ganglia by intracerebral administration of selective neurotoxins.
Herrera-Marschitz, M.; Bustamante, D.; Morales, P.; Goiny, M.
Neurotox Res. 2007 Apr. 11(3-4):169-82. doi: 10.1007/BF03033566.
Determination of the dopamine agonist rotigotine in microdialysates from the rat brain by microbore column liquid chromatography with electrochemical detection.
Kehr, J.; Hu, X.J.; Yoshitake, T.; Scheller, D.
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jan 1. 845(1):109-13. doi: 10.1016/j.jchromb.2006.07.066. Epub 2006 Sep 18.
Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward.
Cagniard, B.; Balsam, P. D.; Brunner, D.; Zhuang, X.
Neuropsychopharmacology. 2006 Jul. 31(7):1362-70. doi: 10.1038/sj.npp.1300966. Epub 2005 Nov 23.
Monitoring brain chemical signals by microdialysis.
Kehr, J.; Yoshitake, T.
American Scientific Publishers. 2006. Vol. 6.
Discovery of novel hippocampal neurogenic agents by using an in vivo stable isotope labeling technique.
Shankaran, M.; King, C.; Lee, J.; Busch, R.; Wolff, M.; Hellerstein, M. K.
J Pharmacol Exp Ther. 2006 Dec. 319(3):1172-81. doi: 10.1124/jpet.106.110510. Epub 2006 Sep 14.
Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.
Rothstein, J. D.; Patel, S.; Regan, M. R.; Haenggeli, C.; Huang, Y. H.; Bergles, D. E.; Jin, L.; Dykes Hoberg, M.; Vidensky, S.; Chung, D. S.; Toan, S. V.; Bruijn, L. I.; Su, Z. Z.; Gupta, P.; Fisher, P. B.
Nature. 2005 Jan 6. 433(7021):73-7. doi: 10.1038/nature03180.
Knock-in mouse models of Huntington’s disease.
Menalled, L. B.
NeuroRx. 2005 Jul. 2(3):465-70. doi: 10.1602/neurorx.2.3.465.
Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP.
Aguirre, J.A.; Kehr, J.; Yoshitake, T.; Liu, F.L.; Rivera, A.; Fernandez-Espinola, S.; Andbjer, B.; Leo, G.; Medhurst, A.D.; Agnati, L.F.; Fuxe, K.
Brain Res. 2005 Feb 8. 1033(2):216-20.
Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT4 receptor knock-out mice.
Compan, V.; Zhou, M.; Grailhe, R.; Gazzara, R. A.; Martin, R.; Gingrich, J.; Dumuis, A.; Brunner, D.; Bockaert, J.; Hen, R.
J Neurosci. 2004 Jan 14. 24(2):412-9. doi: 10.1523/JNEUROSCI.2806-03.2004.
Juvenile 5HT(1B) receptor knockout mice exhibit reduced pharmacological sensitivity to 5HT(1A) receptor activation.
El-Khodor, B. F.; Dimmler, M. H.; Amara, D. A.; Hofer, M.; Hen, R.; Brunner, D.
Int J Dev Neurosci. 2004 Aug-Oct. 22(5-6):405-13. doi: 10.1016/j.ijdevneu.2004.06.001.
Application of triple-probe microdialysis for fast pharmacokinetic/pharmacodynamic evaluation of dopamimetic activity of drug candidates in the rat brain.
Weikop, P.; Egestad, B.; Kehr, J.
J Neurosci Methods. 2004 Dec 30. 140(1-2):59-65. doi: 10.1016/j.jneumeth.2004.06.017.
Striatal plasticity at the network level. Focus on adenosine A(2A) and D(2) interactions in models of Parkinson’s Disease.
Tanganelli, S.; Sandager Nielsen, K.; Ferraro, L.; Antonelli, T.; Kehr, J.; Franco, R.; Ferre, S.; Agnati, L.F.; Fuxe, K.; Scheel-Kruger, J.
Parkinsonism Relat Disord. 2004 Jul. 10(5):273-80. doi: 10.1016/j.parkreldis.2004.02.015.
Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats.
Bustamante, D.; Bustamante, L.; Segura-Aguilar, J.; Goiny, M.; Herrera-Marschitz, M.
Neurotox Res. 2004. 5(8):569-77. doi: 10.1007/BF03033177.
Stress-induced hyperthermia and anxiety: pharmacological validation.
Olivier, B.; Zethof, T.; Pattij, T.; van Boogaert, M.; van Oorschot, R.; Leahy, C.; Oosting, R.; Bouwknecht, A.; Veening, J.; van der Gugten, J.; Groenink, L.
Eur J Pharmacol. 2003 Feb 28. 463(1-3):117-32. doi: 10.1016/s0014-2999(03)01326-8.
In need of high-throughput behavioral systems.
Brunner, D.; Nestler, E.; Leahy, E.
Drug Discov Today. 2002 Sep 15. 7(18 Suppl):S107-12. doi: 10.1016/s1359-6446(02)02423-6.
Neuregulin 1 and susceptibility to schizophrenia.
Stefansson, H.; Sigurdsson, E.; Steinthorsdottir, V.; Bjornsdottir, S.; Sigmundsson, T.; Ghosh, S.; Brynjolfsson, J.; Gunnarsdottir, S.; Ivarsson, O.; Chou, T. T.; Hjaltason, O.; Birgisdottir, B.; Jonsson, H.; Gudnadottir, V. G.; Gudmundsdottir, E.; Bjornsson, A.; Ingvarsson, B.; Ingason, A.; Sigfusson, S.; Hardardottir, H.; Harvey, R. P.; Lai, D.; Zhou, M.; Brunner, D.; Mutel, V.; Gonzalo, A.; Lemke, G.; Sainz, J.; Johannesson, G.; Andresson, T.; Gudbjartsson, D.; Manolescu, A.; Frigge, M. L.; Gurney, M. E.; Kong, A.; Gulcher, J. R.; Petursson, H.; Stefansson, K.
Am J Hum Genet. 2002 Oct. 71(4):877-92. doi: 10.1086/342734. Epub 2002 Jul 23.
Timing and Foraging: Gibbon’s Scalar Expectancy Theory and Optimal Patch Exploitation.
Brunner, D.; Kacelnik, A.
Animal Learning and Behavior 2001. 1. 177-190.
Pharmacology of Temporal Cognition in Two Mouse Strains.
Abner, R.; Edwards, T.; Brunner, D.
Special issue of the International Journal of Comparative Psychology 2001. 14. 189-210.
The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics Psychopharmacology (Berl)
Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor.
Grailhe, R.; Waeber, C.; Dulawa, S. C.; Hornung, J. P.; Zhuang, X.; Brunner, D.; Geyer, M. A.; Hen, R.
Neuron. 1999 Mar. 22(3):581-91. doi: 10.1016/s0896-6273(00)80712-6.
Monitoring chemistry of brain microenvironment: biosensors, microdialysis and related techniques.
Kehr, J.
In Modern techniques in neuroscience research, Johansson, U. W. a. H., Ed. Springer-Verlag GmbH: Heidelberg, Germany, 1999. pp 1149-1198.
Serotonin receptor 1A knockout: an animal model of anxiety-related disorder.
Ramboz, S.; Oosting, R.; Amara, D. A.; Kung, H. F.; Blier, P.; Mendelsohn, M.; Mann, J. J.; Brunner, D.; Hen, R.
Proc Natl Acad Sci U S A. 1998 Nov 24. 95(24):14476-81. doi: 10.1073/pnas.95.24.14476.
